HIMACHAL PRADESH STATE PHARMACY COUNCIL

H.P. STATE PHARMACY COUNCIL

DRUG INFORMATION CENTER

DRUG AND THERAPY BULLETIN

Issue 4, Volume 2 | January 2018

Contact us
at
Laureate Institute of Pharmacy Kathog
Jwala ji, Distt. Kangra. HP 177101

Toll Free 18001210443

Editorial

Advisory Board:

DRUG INFORMATION CENTER
HIMACHAL PRADESH STATE PHARMACY COUNCIL
LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101, Toll Free 18001210443
Phone: 09218428042, 9459220253. E-mail: hpspcdic@gmail.com, dic@hpspc.in

DRUG UPDATES

Procysbi for pediatric patients

On December 27 2017, the US FDA expanded the nephropathic cystinosis indication for Procysbi® (cysteamine bitartrate) oral delayed-release capsules to include pediatric patients 1 year of age or older. Procysbi, which was previously approved to treat pediatric patients 2 years of age or older, is also approved to treat adult patients with nephropathic cystinosis.

Prescribing information can be found at: http://hznp.azureedge.net/public/Procysbi-Prescribing-Info.pdf.

Tasigna D/C eligibility

On December 22, 2017, the US FDA approved a product label update for Tasigna® (nilotinib) oral capsules to reflect that patients being treated with the drug for a minimum of 3 years for Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML-CP) with typical BCR-ABL transcripts and an achieved sustained molecular response (MR4.5, corresponding to = BCR-ABL/ABL less than or equal 0.0032% IS) may be eligible to discontinue (D/C) treatment. After treatment is discontinued, regular monitoring is required to ensure that the disease does not recur.

Prescribing information can be found at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022068s026lbl.pdf.



Schematic representation of Philadelphia chromosome

Giapreza for critically low BP

On December 21, 2017, the US FDA approved Giapreza(TM) (angiotensin II) IV injection to increase blood pressure (BP) in adults with

DRUG INFORMATION CENTER
HIMACHAL PRADESH STATE PHARMACY COUNCIL
LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101, Toll Free 18001210443
Phone: 09218428042, 9459220253. E-mail: hpspcdic@gmail.com, dic@hpspc.in

septic or other distributive shock. Approval, which was granted under priority review, was based on a clinical trial in which a significantly greater number of adult patients responded to angiotensin II compared with placebo. Giapreza was effective in treating hypotension when given with conventional therapy used to lower blood pressure.

Prescribing information can be found at: http://lajollapharmaceutical.com/wp-content/uploads/2017/12/Final-Approved-Label.pdf.

Siklos for pediatric sickle cell anemia

On December 21, 2017, the US FDA approved Siklos® (hydroxyurea) oral tablets to reduce the need for blood transfusions in pediatric patients who are 2 years of age or older with sickle cell anemia with recurrent moderate to severe painful crises. Siklos, which was granted priority review and orphan drug designation, is the first hydroxyurea product to gain FDA approval for pediatric patients with sickle cell anemia. In a clinical trial of pediatric patients 2 to 18 years of age, hydroxyurea use resulted in an increase in hemoglobin F.

Prescribing information can be found at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208843s000lbl.pdf.

Macrilen for AGHD diagnosis

On December 20, 2017, the US FDA approved Macrilen™ (macimorelin) oral granules for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen prompts growth hormone secretion from the pituitary gland into the circulatory system which is then measured in 4 blood samples over 90 minutes following administration.

Prescribing information can be found at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205598s000lbl.pdf.

Rhopressa to reduce IOP

On December 18, 2017, the US FDA approved Rhopressa® (netarsudil) ophthalmic solution indicated to reduce elevated intraocular pressure

(IOP) in patients with open-angle glaucoma or ocular hypertension. Rhopressa, a once-daily eye drop, works to reduce IOP by increasing the outflow of aqueous humor through the trabecular meshwork

Prescribing information can be found at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208254lbl.pdf.

DRUG INFORMATION CENTER
HIMACHAL PRADESH STATE PHARMACY COUNCIL
LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101, Toll Free 18001210443
Phone: 09218428042, 9459220253. E-mail: hpspcdic@gmail.com, dic@hpspc.in

PHARMA NEWS

USFDA allow marketing of the Dermapace System to treat diabetic foot ulcers

The U.S. Food and Drug Administration permitted the marketing of the Dermapace System, the first shock wave device intended to treat diabetic foot ulcers.

The Dermapace System is intended to be used in the treatment of chronic, full-thickness diabetic foot ulcers with wound areas measuring no larger than 16 cm^2 (about the size of a soda can top) which extend through the epidermis, dermis, tendon, or capsule, but without bone exposure. The Dermapace System is an external (extracorporeal) shock wave system that uses pulses of energy, similar to sound waves, to mechanically stimulate the wound. The device is intended for adult patients (22 years and older), presenting with diabetic foot ulcers lasting for more than 30 days, and should be used along with standard diabetic ulcer care.

Teva Announces Exclusive Launch of Generic Version of Reyataz® in the United States

Teva Pharmaceutical Industries Ltd announced the exclusive launch of a generic version of Reyataz®1 (atazanavir) capsules in the U.S. Atazanavir sulfate capsules are a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection for patients 6 years and older weighing at least 15 kg. “The exclusive launch of our generic version of Reyataz marks our fifth generic product offering for the treatment of HIV-1 infection,” said Brendan O’Grady, Executive Vice President, North America Commercial at Teva.

Lupin receives FDA approval for generic Dovonex Scalp Solution

Lupin announced that it has received final approval for its Calcipotriene Topical Solution, 0.005% (Scalp Solution) from the United States Food and Drug Administration (FDA) to market a generic version of Dovonex Scalp Solution, 0.005% of Leo Pharmaceutical Products Ltd.

Rhizen Pharmaceuticals receives USFDA approval for Tenalisib (RP6530)

Rhizen Pharmaceuticals S.A., announced that the U.S. Food and Drug Administration (FDA) has

granted orphan-drug designation for the active moiety of Tenalisib (RP6530), the Company's highly selective and orally active dual PI3K delta/gamma inhibitor, for treatment of peripheral T-cell lymphoma (PTCL).

USFDA approves Dr. Reddy's Laboratories Melphalan Hydrochloride Injection

Dr. Reddy's Laboratories Ltd that it has launched Melphalan Hydrochloride for Injection, a therapeutic equivalent generic version of Alkeran® (melphalan hydrochloride) for Injection in the United States market approved by the U.S. Food and Drug Administration (USFDA).

No impact on prices of Essential Drugs post introduction of GST in India

It is noticed that there will be almost no impact on the prices of non-scheduled formulations which account for nearly 80% of the total pharmaceuticals sector, analysed by government.

In respect of Scheduled formulations, there is no impact on the prices of about 4% formulations, which mainly include formulations related to Immunization Program, Anti-cancer, Oral rehydration salts, Contraceptives etc. In most of the remaining formulations, which account for nearly 16% of total pharmaceutical sector, there is an

increase in the prices to the extent of nearly 2.30%, the Minister informed.

Lincoln Pharma received Patent for Antimalarial Drug

Lincoln Pharmaceuticals Ltd. has been awarded a Patent for "An Arteether Injection for Treatment of Malaria", Patent No.258915 by Government of India for Antimalarial Drug. In the present time, this formulation, "Arteether injection" are available in market in 3ml and 2ml ampules form. At the time of injecting "Arteether Injection" to the patient by doctors, it is very painful for a long time. Patient will have to take this injection at least for a period of three days to control the malaria.

List of Clinical Trials to be inspected in the year 2018

Sl. No.	Name of Investigational Product	Study Title
1	Recombinant Quadrivalent Human Papilloma Virus	A Phase-I, open label clinical trial to assess the safety and tolerability of recombinant Quadrivalent Human Papilloma Virus (qHPV) (type 6,11, 16,18) vaccine manufactured by Serum Institute of India Pvt. Ltd. in healthy adult volunteers.
2	Tetanus Vaccine	A Phase I open label study to evaluate the safety of Tetanus Vaccine (Adsorbed) in Healthy Indian Adults.
3	HPV Vaccine	An open label, single treatment, single period, single dose, clinical phase I study to assess the safety and tolerability of Bivalent Papillomavirus (Types 16L1 & 18L1) vaccine of M/s Cadila Healthcare Ltd., India adult female human subjects.
4	Zika Virus Vaccine	A Phase I, multicenter, double-blind, placebo controlled, randomized (Intra group) Clinical trial to evaluate two dose of three sequentially escalating cohort of Zika Virus vaccine, inactivated (Adsorbed) (BBV121) in healthy adult Dengue Sero- negative and dengue Seroposiive Volunteers
5	r-BCG Vaccine	A multicenter Phase II/III double-blind, randomized, Placebo controlled study to evaluate the efficacy And safety of VPM1002 in the prevention of tuberculosis (TB) recurrence in pulmonary TB patients after successful TB treatment in India
6	Hapititis A Vaccine	A Prospective, Multicentre, Randomized, Double Blind, Parallel Group, Phase III Study Comparing Immunogenicity, Safety, and Tolerability of Single Dose of Hepatitis A (Live) Vaccine, Freeze-dried from Sinopharm versus BiovacTM-A (Freeze-dried Live Attenuated Hepatitis A Vaccine) from Wockhardt in Healthy Indian Children.

DRUG INFORMATION CENTER
HIMACHAL PRADESH STATE PHARMACY COUNCIL
LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101, Toll Free 18001210443
Phone: 09218428042, 9459220253. E-mail: hpspcdic@gmail.com, dic@hpspc.in

Sl. No.	Name of Investigational Product	Study Title
7	MR Vaccine	A prospective, randomized, two arm, single blind, parallel, active controlled, multicentre,phase III clinical study to evaluate the immunogenicity and safety of Inactivated Influenza vaccine (split virion) I.P. (Tetravalent) of M/s Cadila Healthcare Limited in healthy children aged 6 months to 17 years.
8	Inactivated Influenza vaccine (splitvirion) I.P. (Tetravalent)	A prospective, randomized, two arm, single blind, parallel, active controlled, multicentre,phase III clinical study to evaluate the immunogenicity and safety of Inactivated Influenza vaccine (split virion) I.P. (Tetravalent) of M/s Cadila HealthcareLimited in healthy children aged 6 months to ?????
9	Inactivated Influenza vaccine (splitvirion) I.P. (Trivalent)	A prospective, randomized, two arm, single blind, parallel, active controlled, multicentre, phase III clinical study to evaluate the immunogenicity and safety of Inactivated Influenza vaccine (split virion) I.P.(Trivalent) of M/s Cadila Healthcare Limitedin healthy children aged 6 months to 17years
10	Tetanus Vaccine	An open- label, single treatment, single-period, single dose, clinical phase I study to assess the safety and tolerability of tetanus vaccine of M/S Bio Vaccine (India) Private Limited in healthy, adult, male, human subjects.
11	Diptheria, Tetanus, Pertussis (whole cell), Hepatitis B(rDNA) and Haemophilus influenzae type b conjugate vaccine (Adsorbed)	A Prospective, randomized, two arm, single blind, parallel active-controlled, multicenter, non-inferiority clinical study to evaluate the immunogenicity and safety of Diptheria, Tetanus, Pertussis (whole cell), Hepatitis B(rDNA) and Haemophilus influenzae type b conjugate vaccine (Adsorbed) of M/S Cadila Healthcare Limited compared to Diphtheria, Tetanus, Pertussis (whole cell), Hepatitis B(rDNA) and Haemophilus influenzae type b conjugate vaccine (Adsorbed) of M/S Panacea Biotech Limited in Healthy infants.

Sl. No.	Name of Investigational Product	Study Title
12	Tetanus Vaccine	A Prospective, age decending, randomized, two arm, single blind, parallel, active controlled, multicentre, non-inferiority, Phase II/III clinical study to evaluate the immuniginity and safety of Tetanus Vaccine (Adsorbed) of M/s bio Vaccines (India) Private Limited compared to Tetanus Vaccine (Adsorbes) of M/s Serum Insitute of India Limited in healthy subjects aged 10-60 years of age.
13	Inactivate Hapititis-A Vaccine	An Open Label Phase I Study to evaluate the Safety and Immuniginicity of Inactivated Hepatitis-A Vaccine when administered as a Single Dose in two groups of Healthy Subjects of 19 to 49 years and 12 to 18 years of age.
14	Rotavirus Vaccine	A Phase II/III, multicenter, open-label, randomized study of liquid Bovine rotavirus Pentavalent vaccine (LBRV-PV) to evaluate lot-to-Lot consistency and to compare non-inferiority with ROTASIIL (lyophilized BRV-PV) in healthy infants in India
15	Diphtheria-Tetanus-Acellular Pertusis-Inactivated Polivirus Type I, II & III and Haemophilus Influenza Type b Titanus Toxiod Conjugate Vaccine (Infanrix-IPV/Hib) (SB213503)	A Phase III, open-label, multicentre study to evaluate the immuniginicity and safety of GSK Biologicals' Combined Diphtheria-Tetanus-Acellular Pertusis-Inactivated Polivirus Type I, II & III and Haemophilus Influenza Type b Titanus Toxiod Conjugate Vaccine (Infanrix-IPV/Hib) (SB213503) administered at 6, 10 and 14 weeks in 112 healthy Indian infants.
16	14-Valent Pneumococcal Vaccine	Phase II clinical trial titled "An open label parallel randomized Phase II comparative study to evaluate safety tolerability and immunogenicity of two intramuscular doses of 14 valent pneumococcal polysaccharide conjugate vaccine administered 2 months apart to 12 to 23 months old healthy Indian PCV naive toddlers.

Note

If anyone would like to publish his/her article in the monthly bulletin of Drug Information Center regarding Pharma updates, they can send their articles with their full address and professional status on the following reference before 25th of the every month.

Mail ID: hpspcdic@gmail.com

Toll Free: 18001210443, Tel: 9218428042,
Whatsapp: 9459220253

DRUG INFORMATION CENTER
HIMACHAL PRADESH STATE PHARMACY COUNCIL
LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101, Toll Free 18001210443
Phone: 09213428042, 9459220253. E-mail: hpspcdic@gmail.com, dic@hpspc.in



Notice from CDSCO

The central drug standard control organization (CDSCO) in pursuance to implementation of E-governance has launched an online portal 'SUGAM' on 14-11-2015. In this regard for filling of application in clinical trial, marketing authorization, registration certificate and import license of human vaccines has already been initiated with effect from 06-02-2017 in 'SUGAM' portal.

In view of above it has been decided that applications pertaining to clinical trial, marketing authorization, registration certificate and import license of human vaccines shall be accepted only through online mode from 1st Jan 2018 and no offline application accepted thereafter.

List of new drug approved from 01-01-2017 till date by New Drugs Division

Sl. No.	Name of drug	Indication	Date of issue
1	Hydrocortisone Aceponate 0.584mg/ml Cutaneous Spray Solution (Vet.)	For symptomatic treatment of inflammatory and pruritic dermatosis in dogs.	06-01-17
2	Dexlansoprazole Delayed Release Capsule 30/60mg & Bulk	For the treatment of: I) Healing of all grades of erosive esophagitis (EE). ii) Maintaining healing of EE and relief of heartburn. iii) Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD).	16-01-17

DRUG INFORMATION CENTER
HIMACHAL PRADESH STATE PHARMACY COUNCIL
LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101, Toll Free 18001210443
Phone: 09218428042, 9459220253. E-mail: hpspcdic@gmail.com, dic@hpspc.in

Sl. No.	Name of drug	Indication	Date of issue
3	Carfilzomib Sterile Lyophilized Powder for Injection 60mg/vial (50ml vial)	Relapsed or refractory multiple myeloma Carfilzomib for injection is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. Carfilzomib for injection is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.	17-01-17
4	Dabrafenib 50mg/75mg Capsules (Dabrafenib Mesylate)	As a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an appropriate test. In combination with Trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an appropriate test.	18-01-17
5	Trametinib 0.5mg/2mg Tablets (Trametinib Dimethyl Sulfoxide)	As a monotherapy and in combination with Dabrafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an appropriate test.	18-01-17
6	Alectinib 150mg Capsules (Alectinib Hydrochloride)	For the treatment of patients with anaplastic lymphoma kinase (ALK)-Positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to Crizotinib.	23-01-17
7	Eliglustat 84mg Capsules (Eliglustat Tartrate or Hemitartrate Salt)	For the long term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an appropriate test.	31-01-17

DRUG INFORMATION CENTER
HIMACHAL PRADESH STATE PHARMACY COUNCIL
LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101, Toll Free 18001210443
Phone: 09218428042, 9459220253. E-mail: hpspcdic@gmail.com, dic@hpspc.in

Sl. No.	Name of drug	Indication	Date of issue
8	Pasireotide long-acting release 20/40/60mg powder for suspension for injection (Additional Indication) (Pasireotide pamoate)	For the treatment of patients with acromegaly who have had an inadequate response to surgery and/ or for whom surgery is not an option.	14-02-2017
9	Etonogestrel 68 mg implant	For use by women to prevent pregnancy.	15-02-2017
10	Bepotastine Besilate 1.5% w/v Ophthalmic solution	For the treatment of itching associated with allergic conjunctivitis	22-02-2017
11	Dienogest 2mg Tablets	For the management of Pelvic pain associated with Endometriosis	09-03-2017
12	Eprinomectin 0.5% for beef and dairy cattle (vet.)	It is indicated for the treatment and control of gastrointestinal roundworm (including inhibited Ostertagia ostertagi), lungworm, grubs, sucking and biting lice, chlorioptic and sarcoptic-mange mites, and horn flies in beef and dairy cattle of all ages, including lactating dairy cattle.	14-03-2017
13	Bepotastine Besilate 10 mg Tablets	For the treatment of allergic rhinitis	27-03-2017
14	Prucalopride 1mg/2mg Tablet & Bulk (Prucalopride Succinate)	For the treatment of chronic idiopathic constipation in adults in whom laxatives fail to provide adequate relief	13-04-2017
15	Teriflunomide 14 mg tablets	For the treatment of patients with relapsing form of multiple sclerosis	13-04-2017
16	Pomalidomide 1mg/2mg/3mg/4mg Capsules & Bulk	In combination with dexamethasone, for patient with patient multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.	01-05-2017

DRUG INFORMATION CENTER
HIMACHAL PRADESH STATE PHARMACY COUNCIL
LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101, Toll Free 18001210443
Phone: 09218428042, 9459220253. E-mail: hpspcdic@gmail.com, dic@hpspc.in

Sl. No.	Name of drug	Indication	Date of issue
17	Sofosbuvir 400 mg +Velpatasvir 100 mg Tablet	For the treatment of adult patients with -chronic Hepatitis C virus, Genotype 1,2,3,4,5 or 6 infection. – Without cirrhosis or with compensated cirrhosis – With decompensated with chronic for use in combination with Ribavirin.	04-05-2017
18	Velpatasvir Bulk		04-05-2017
19	Osimertinib 40 mg/80 mg Film coated Tablets (Osimertinib Mesylate)	For the treatment of patient with metastatic epidermal growth factor receptor (EGFR) T790 M mutation-positive non-small cell lung cancer (NSCLC), as detected by an appropriate test, whose disease has progressed on or after EGFR TKI therapy	29-05-2017
20	Argatroban Hydrate Bulk & Injection 250 mg/ 2.5 ml	1) For prophylaxis or treatment of thrombosis in adult patients with Heparin induced thrombocytopenia (HIT). 2) As an anticoagulant in adults patients with or at risk for heparin-induced thrombocytopenia undergoing percutaneous coronary intervention (PCI)	30-05-2017
21	Fluralaner chewable tablets 112.5 mg/ 250 mg/500mg/ 1000mg/1400 mg	For the treatment of tick and flea infestations on dogs for 12 weeks. This veterinary medicinal product is a systemic insecticide and acaricide with a long duration of action that provides immediate and persistent tick (adult and juvenile *Ixodes ricinus, Ixodes hexagonus, Ixodes scapularis, Ixodes holocyclus*, *Dermacentor reticulates, Dermacentor variabilis* and *Rhipicephalus sanguineus*) and flea (Ctenocephalides felis and Ctenocephalides canis) killing activity for 12 weeks. Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance. the onset of effect is within 8 hours of attachment for fleas (*C. felis*) and 12 hours of attachment for ticks (*I. ricinus*)	30-05-2017

Sl. No.	Name of drug	Indication	Date of issue
21	Fluralaner chewable tablets 112.5 mg/250 mg/500mg/1000mg/ 1400 mg (*Continued*)	The product effectively controls environmental flea population in area to which treated dogs have access. The product can be used as part of an treatment strategy for the control of Flea Allergy Dermatitis (FAD)	30-05-2017
22	Fluticasone Furoate (100 mg mcg) and Vilanterol Trifenatate (25 mcg) powder for inhalation	Indicated for the maintenance treatment of the airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and / or emphysema and to reduce exacerbation of COPD in patients with an exacerbation history.	29-06-2017
23	Mirabegron Prolonged Release Tablet 25 mg / 50 mg	Symptomatic treatment of urgency, increased micturition frequency and / or urgency incontinence as may occur in patients with over active bladder (OAB) Syndrome	12-07-2017
24	Delamanid 50 mg tablet	For the use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability	02-08-2017
25	Mirabegron Prolonged Release Tablet 25 mg /50 mg & Bulk	Symptomatic treatment of urgency, increased micturition frequency and / or urgency incontinence as may occur in patients with over active bladder (OAB) Syndrome	18-08-2017
26	Efonidipine Hydrochloride Ethanolate Bulk & Tablets 10 mg/20mg/40mg	Indicated for the management of • Hypertension • Renal parenchymal hypertension • Angina	28-08-2017
27	Brivaracetam Film Coated Tablets 50mg/75mg/100mg	As adjunctive therapy in the treatment of partial – onset seizures in patients 16 years of age and older with epilepsy	07-09-2017

DRUG INFORMATION CENTER
HIMACHAL PRADESH STATE PHARMACY COUNCIL
LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101, Toll Free 18001210443
Phone: 09218428042, 9459220253. E-mail: hpspcdic@gmail.com, dic@hpspc.in

Sl. No.	Name of drug	Indication	Date of issue
28	Treosulfan Bulk & injection 5g/vial	For the conditioning treatment prior to haematopoetic stem-cell transplantation	26-09-2017
29	Ribociclib 200 mg Film coated Tablets	In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of post menopausal women with the hormone receptor (HR)-Positive, human epidermal growth factor receptor 2 (HER2)-Negative advanced or metastatic breast cancer	27-09-2017
30	Dienogest Bulk & 2mg Tablet	For the management of Pelvic pain associated with Endometriosis	28-09-2017
31	Apremilast bulk & film coated tablets 10 mg/ 20 mg/30 mg	for treatment of patients with moderate to severe plaque psoriasis who are candidate for phototherapy or systemic therapy	13-10-2017
32	Arbekacin bulk & Injection 200mg/4ml	Treatment of following infections caused by Methicillin resistant *Staphylococcus aureus* (MRSA), sepsis pneumonia	20-10-2017
33	Benestermycin Intra-mammary suspension (vet.)	For the treatment of subclinical mastitis at drying off, and the prevention of new bacterial infections of the udder during the dry period in dairy cows, caused by bacteria susceptible to penicillin and framycetin	03-11-2017
34	Midostaurin 25 mg Capsules	• In combination with standard induction and consolidation chemotherapy followed by single agent in maintenance of therapy for adult patients with newly diagnosed with acute myeloid leukemia (AML) who are FLT-3 Mutation positive. • For the treatment of adult patients with advanced systemic mastocycosis (Advanced SM)	09-11-2017
35	Tenofovir Alafenamide Fumarate bulk & 25 mg capsules	For the treatment of chronic Hepatitis B virus infection in adults with compensated liver disease	10-11-2017

DRUG INFORMATION CENTER
HIMACHAL PRADESH STATE PHARMACY COUNCIL
LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101, Toll Free 18001210443
Phone: 09218428042, 9459220253. E-mail: hpspcdic@gmail.com, dic@hpspc.in



Sl. No.	Name of drug	Indication	Date of issue
36	Arteolane Maleate and Piperaquine phosphate Dispersible tablets (37.5 mg +187.5 mg	Indicated in children aged 6 months to 12 years for the treatment of : – Acute uncomplicated Plasmodium falciparum malaria infection – Acute uncomplicated Plasmodium Vivax malaria infection	24-11-2017
37	Macitentan Bulk and Tablets 10 mg	Macitentan is an endothelin receptor antagonist (ERA)l indicated for the treatment of Pulmonary arterial hypertension (PAH, WHO group I) to delay disease progression	07-12-2017

Note

If anyone would like to publish his/her article in the monthly bulletin of Drug Information Center regarding Pharma updates, they can send their articles with their full address and professional status on the following reference before 25th of the every month.

Mail ID: hpspcdic@gmail.com

Toll Free: 18001210443, Tel: 9218428042,
Whatsapp: 9459220253

Which kind of queries can be asked from Drug Information Center... ?

It is the matter of pride for all the population of Himachal Pradesh that there is **Drug Information Center** (DIC) in the state which is giving the services to promote the rational drug use. Maximum population of state knows that there is DIC, but they are unaware about the services of the DIC. They all are confused that which kind of queries they can ask.

There is no any restriction to take the drug query information by any one. Any person (physician, pharmacist, nurse, patient, people of community, old persons, students, researchers etc.) can come in or call in the DIC office to take drug information.

Following kinds of queries regarding drugs can be asked from DIC:

- If patient is administering two medicines at the same time then he/she before administering the medicine, can confirm from DIC that this combination is safe or not safe. If combination will be not safe then it may also be life threatening.
- If patient is administering a medicine then he/she can confirm which kinds of foods have to be avoided.
- Someone can confirm that use of any specific medicine in particular condition (like as pregnancy/ lactation) is safe or not safe.
- General information about drug identification can also be taken from the DIC, like as use and side/adverse effects, time of administration, duration of administration, dose in different age groups etc. about any drug.
- Information about substituted drugs with different prices can also be provided by DIC.
- Any updation about medicines can be confirmed from DIC.

DIC will provide the accurate information on request without any fear and favor.

In short, it can be say that DIC can provide any kind of information about any medicine to any one without any cost.

Personnel can assess directly, can call in the DIC office, sent the query by post, by E-mail on following address:

Drug Information Center, Run by Himachal Pradesh State Pharmacy council at Laureate Institute of Pharmacy Kathog, jwala ji, Distt. Kangra HP 177101

Toll Free: 18001210443
Tel. 9218428042
e-mail: hpspcdic@gmail.com

Toll Free: 18001210443

DRUG INFORMATION CENTER
HIMACHAL PRADESH STATE PHARMACY COUNCIL
LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101, Toll Free 18001210443
Phone: 09218428042, 9459220253. E-mail: hpspcdic@gmail.com, dic@hpspc.in

H.P. STATE PHARMACY COUNCIL

Wishing You a Healthy Life

Scan this Quick Response (QR) code to know more

You may download any QR code scanner from Play Store/iTunes

DRUG INFORMATION CENTER

HIMACHAL PRADESH STATE PHARMACY COUNCIL

Laureate Institute of Pharmacy, Kathog, Jwala Ji, Distt. Kangra HP 177101

Website: www.hpspc.in | Mail ID: hpspcdic@gmail.com, dic@hpspc.in

Toll Free 18001210443, Phone: 09218428042, 9459220253